The morally ground-shifting legacy of Ian Wilmut and Dolly the sheep
By Gregory E. Kaebnick,
STAT
| 09. 15. 2023
Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10, leaving behind a twofold legacy. One part is groundbreaking science. Creating Dolly required a combination of genome manipulation and reproductive tools that helped launch what is sometimes called “reprogenetics,” a basket of reproductive and genetic technologies that allow for greater control over human procreation and generated work that ranges from human-animal chimeras to the “de-extinction” of mammoths. By demonstrating that differentiated adult cells could be forced by the right chemical signals to become pluripotent stem cells, Wilmut’s work also provided the basis for Shinya Yamanaka’s Nobel Prize-winning work.
Besides being groundbreaking science, Dolly was morally ground-shifting. Perhaps more than any other biotech advance, Dolly symbolized growing human power over nature. But the Dolly project was deeply troubling to most observers. Kept a close secret by the Roslin Institute and initially disclosed in a media leak in 1997, about eight months after her birth, Dolly caught everyone by surprise. At the same time, genetically modified crops were being rolled out quickly and...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...